(Q54340378)

28 May 2018

title

Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. (English)

1 reference

28 May 2018

author

José María López-Picazo

6

1 reference

28 May 2018

José Luis Pérez-Gracia

10

1 reference

28 May 2018

author name string

Carlos Caicedo

1

1 reference

28 May 2018

Maria Jose Garcia-Velloso

2

1 reference

28 May 2018

Maria Dolores Lozano

3

1 reference

28 May 2018

Tania Labiano

4

1 reference

28 May 2018

Carmen Vigil Diaz

5

1 reference

28 May 2018

Alfonso Gurpide

7

1 reference

28 May 2018

Javier J Zulueta

8

1 reference

28 May 2018

Jose Angel Richter Echevarria

9

1 reference

28 May 2018

publication date

3 July 2014

1 reference

28 May 2018

European Journal of Nuclear Medicine and Molecular Imaging

published in

1 reference

28 May 2018

volume

41

1 reference

28 May 2018

issue

11

1 reference

28 May 2018

page(s)

2058-2065

1 reference

28 May 2018

https://scigraph.springernature.com/pub.10.1007/s00259-014-2833-4

exact match

0 references

cites work

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Sex and SUVmax: sex-dependent prognostication in early non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Akt stimulates aerobic glycolysis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

KRAS mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2833-4

Correlation of Glut-1 glucose transporter expression with [(18)F]FDG uptake in non-small cell lung cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24990403

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24990403

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24990403

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00259-014-2833-4

1 reference

28 May 2018

1 reference

28 May 2018